Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 4 | 2024 | 571 | 1.390 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2021 | 17 | 0.690 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 127 | 0.620 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 234 | 0.590 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 573 | 0.540 |
Why?
|
| Immunotherapy | 1 | 2021 | 748 | 0.470 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1038 | 0.440 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2024 | 158 | 0.360 |
Why?
|
| Hydroxyurea | 1 | 2024 | 85 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 175 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2023 | 201 | 0.190 |
Why?
|
| Afibrinogenemia | 1 | 2021 | 10 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 344 | 0.170 |
Why?
|
| Fibrinogen | 1 | 2021 | 157 | 0.160 |
Why?
|
| Burkitt Lymphoma | 1 | 2021 | 141 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2021 | 87 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2021 | 195 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1451 | 0.140 |
Why?
|
| Prognosis | 3 | 2021 | 5008 | 0.130 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2016 | 23 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 1192 | 0.110 |
Why?
|
| Soft Tissue Infections | 1 | 2016 | 91 | 0.110 |
Why?
|
| Intellectual Disability | 1 | 2022 | 1093 | 0.110 |
Why?
|
| Child | 5 | 2024 | 25758 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 816 | 0.110 |
Why?
|
| Phenotype | 1 | 2021 | 4541 | 0.090 |
Why?
|
| Genomics | 1 | 2020 | 1651 | 0.090 |
Why?
|
| Hospitals, Pediatric | 1 | 2016 | 780 | 0.090 |
Why?
|
| Hematopoiesis | 2 | 2023 | 225 | 0.090 |
Why?
|
| Humans | 9 | 2024 | 132105 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2016 | 698 | 0.080 |
Why?
|
| Epithelial Sodium Channels | 1 | 2009 | 16 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 763 | 0.080 |
Why?
|
| Protons | 1 | 2009 | 98 | 0.080 |
Why?
|
| Sodium Channels | 1 | 2009 | 104 | 0.070 |
Why?
|
| Adolescent | 3 | 2024 | 20532 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2009 | 422 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 761 | 0.060 |
Why?
|
| Mice | 4 | 2024 | 18566 | 0.060 |
Why?
|
| Antisickling Agents | 1 | 2024 | 18 | 0.060 |
Why?
|
| Splenic Diseases | 1 | 2024 | 31 | 0.050 |
Why?
|
| Splenomegaly | 1 | 2024 | 33 | 0.050 |
Why?
|
| Calcium | 1 | 2009 | 1083 | 0.050 |
Why?
|
| Splenectomy | 1 | 2024 | 62 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 2553 | 0.050 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2023 | 50 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 1132 | 0.050 |
Why?
|
| Animals | 5 | 2024 | 34953 | 0.050 |
Why?
|
| Ikaros Transcription Factor | 1 | 2021 | 32 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 204 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2023 | 554 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 2453 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1454 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 2659 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2024 | 3873 | 0.030 |
Why?
|
| Ohio | 1 | 2016 | 87 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1975 | 0.030 |
Why?
|
| Infant | 2 | 2024 | 13039 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 14718 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 749 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 4764 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 454 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 4694 | 0.030 |
Why?
|
| Degenerin Sodium Channels | 1 | 2009 | 3 | 0.020 |
Why?
|
| Spider Venoms | 1 | 2009 | 8 | 0.020 |
Why?
|
| Acid Sensing Ion Channels | 1 | 2009 | 5 | 0.020 |
Why?
|
| Female | 3 | 2024 | 70680 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2009 | 124 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 309 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2009 | 295 | 0.020 |
Why?
|
| Point Mutation | 1 | 2009 | 350 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 764 | 0.020 |
Why?
|
| Oocytes | 1 | 2009 | 291 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 1891 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6249 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17374 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 846 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 6445 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2674 | 0.010 |
Why?
|
| Male | 2 | 2024 | 64918 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3778 | 0.010 |
Why?
|